Will pharmacogenomics disrupt the U.S. health care system? No

Public Health Genomics

Volumn 12, Issue 3, 2009, Pages 185-190

  Garrison, L P ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cost effectiveness; Creative destruction; Disruptive innovation; Health reform

Indexed keywords

CLINICAL PRACTICE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PUBLIC HEALTH; REVIEW; UNITED STATES; ECONOMICS; HEALTH CARE POLICY; PHARMACOGENETICS;

DELIVERY OF HEALTH CARE; HEALTH POLICY; HUMANS; PHARMACOGENETICS; UNITED STATES;

EID: 64549137668     PISSN: 16624246     EISSN: None     Source Type: Journal    
DOI: 10.1159/000189632     Document Type: Review

References (25)

1. Enthoven AC: Consumer-Choice Health plan (second of two parts). A national-health-insurance proposal based on regulated competition in the private sector. N Engl J Med 1978;298:709-720.
2. Catlin A, Cowan C, Hartman M, Heffler S; National Health Expenditure Accounts Team: National health spending in 2006: a year of change for prescription drugs. Health Aff (Millwood) 2008;27:14-29.
3. Emanuel EJ, Fuchs VR: Health care vouchers - a proposal for universal coverage. N Engl J Med 2005;352:1255-1260.
4. Congressional Budget Office: The Long-Term Outlook for Health Care Spending. 2007. http://www.cbo.gov/ftpdocs/87xx/doc8758/11-13-LT-Health.pdf.
5. Trusheim MR, Berndt ER, Douglas FL: Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007;6:287-293.
6. Bala MV, Zarkin GA: Pharmacogenomics and the evolution of healthcare: is it time for cost-effectiveness analysis at the individual level? Pharmacoeconomics 2004;22:495-498.
7. Johnson JA: Pharmacogenetics: potential for individualized drug therapy through genetics. Trends Genet 2003;19:660-666.
8. Garrison LP, Austin MJF: The economics of personalized medicine: a model of incentives for value creation and capture. Drug Inf J 2007;41:501-509.
9. Christensen CM: The Innovators Dilemma: When New Technologies Cause Great Firms to Fail. Boston, Harvard Business School Press, 1997.
10. Hwang J, Christensen CM: Disruptive innovation in health care delivery: a framework for business-model innovation. Health Aff (Millwood) 2008;27:1329-1335.
11. Pauly MV: We aren't quite as good, but we sure are cheap: prospects for disruptive innovation in medical care and insurance markets. Health Aff (Millwood) 2008;27:1349-1352.
12. Garrison LP, Veenstra DL, Carlson RJ, Carlson JJ, Meckley LM: Backgrounder on Pharmacogenomics for the Pharmaceutical and Biotechnology Industries: Basic Science, Future Scenarios, Policy Directions - Final Report. Pharmaceutical Outcomes Research Policy and Program. Department of Pharmacy. University of Washington, February, 2007.
13. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology; College of American Pathologists: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.
14. Alfirevic A, Pirmohamed M: Adverse drug reactions and pharmacogenomics: recent advances. Future Medicine 2008;5:11-23.
15. Burckart GJ: Pharmacogenomic research meets clinical practice: example of incorporating pharmacogenomic principles into clinical practice. American College of Clinical Pharmacy Meeting, Phoenix, April 2008. http://www.fda.gov/ Cder/genomics/presentations/ACCP-GJB-Apr-2008.pdf.
16. Huang SM: Warfarin pharmacogenetic testing is now ready for prime time. AACC Annual Meeting, Washington, DC, 2008. http://www.fda.gov/Cder/genomics/ presentations/Huang-July-28-2008-AACC-final.pdf.
17. Rothschild M, Stiglitz JE: Equilibrium in competitive insurance markets: an essay on the economics of imperfect information. Q J Econ 1976;100:629-650.
18. Garrison LP, Austin MJF: Linking pharmacogenetics-based diagnostics and pharmaceuticals for personalized medicine: scientific and economic challenges. Health Aff (Millwood) 2006;25:1281-1290.
19. vB Hjelmborg J, Iachine I, Skytthe A, Vaupel JW, McGue M, Koskenvuo M, Kaprio J, Pedersen NL, Christensen K: Genetic influence on human lifespan and longevity. Hum Genet 2006;119:312-321.
20. Thompson D: Miracle Drug: Only $350,000 a Year. Time Magazine, 1993. http://www.time.com/time/magazine/article/0,9171,977906,00.html.
21. Genetic Information Nondiscrimination Act of 2008. H.R. 493. http://www.govtrack.us/congress/bill.xpd?bill=h110-493.
22. Transcript: Bob Abernethy's interview with Dr. Francis Collins, director of the human genome project at the national institutes of health. Religion and Ethics Newsweekly. 2000. http://www.pbs.org/wnet/religionandethics/transcripts/ collins.html.
23. Hunter DJ, Altshuler D, Rader DJ: From Darwin's finches to canaries in the coal mine - mining the genome for new biology. N Engl J Med 2008;358:2760-2763.
24. Adams CP, Brantner VV: New Drug Development: Estimating entry from human clinical trials. Bureau of Economics, Federal Trade Commission, 2003. http://www.ftc.gov/be/workpapers/wp262.pdf.
25. Murphy KM, Topel RH: The value of health and longevity. J Polit Econ 2006;114:871-904.